Open-Angle Glaucoma - Pipeline Review, H2 2016

  • ID: 3876156
  • Report
  • 123 pages
  • Global Markets Direct
1 of 6

FEATURED COMPANIES

  • Allergan Plc
  • F. Hoffmann-La Roche Ltd.
  • Isarna Therapeutics GmbH
  • Laboratoires Thea S.A.
  • Otsuka Holdings Co., Ltd.
  • Sanofi
  • MORE
Open-Angle Glaucoma - Pipeline Review, H2 2016

Summary

‘Open-Angle Glaucoma - Pipeline Review, H2 2016’, provides an overview of the Open-Angle Glaucoma pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Open-Angle Glaucoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Open-Angle Glaucoma and features dormant and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Open-Angle Glaucoma
- The report reviews pipeline therapeutics for Open-Angle Glaucoma by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Open-Angle Glaucoma therapeutics and enlists all their major and minor projects
- The report assesses Open-Angle Glaucoma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Open-Angle Glaucoma

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Open-Angle Glaucoma
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Open-Angle Glaucoma pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
READ MORE
Note: Product cover images may vary from those shown
2 of 6

FEATURED COMPANIES

  • Allergan Plc
  • F. Hoffmann-La Roche Ltd.
  • Isarna Therapeutics GmbH
  • Laboratoires Thea S.A.
  • Otsuka Holdings Co., Ltd.
  • Sanofi
  • MORE
List of Tables

List of Figures

Introduction

Report Coverage

Open-Angle Glaucoma Overview

Therapeutics Development

Pipeline Products for Open-Angle Glaucoma - Overview

Pipeline Products for Open-Angle Glaucoma - Comparative Analysis

Open-Angle Glaucoma - Therapeutics under Development by Companies

Open-Angle Glaucoma - Therapeutics under Investigation by Universities/Institutes

Open-Angle Glaucoma - Pipeline Products Glance

Late Stage Products

Clinical Stage Products

Early Stage Products

Open-Angle Glaucoma - Products under Development by Companies

Open-Angle Glaucoma - Products under Investigation by Universities/Institutes

Open-Angle Glaucoma - Companies Involved in Therapeutics Development

Aerie Pharmaceuticals, Inc.

Allergan Plc

Amakem NV

Bausch & Lomb Incorporated

F. Hoffmann-La Roche Ltd.

Glaukos Corporation

Inotek Pharmaceuticals Corporation

Isarna Therapeutics GmbH

Kowa Company, Ltd.

Laboratoires Thea S.A.

Laboratorios Sophia S.A. de C.V.

Lee's Pharmaceutical Holdings Limited

Lexicon Pharmaceuticals, Inc.

Ocular Therapeutix, Inc.

Otsuka Holdings Co., Ltd.

Oxford BioMedica Plc

Sanofi

Santen Pharmaceutical Co., Ltd.

Senju Pharmaceutical Co., Ltd.

Sun Pharma Advanced Research Company Ltd.

Sylentis S.A.U.

ViSci Ltd.

Open-Angle Glaucoma - Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Combination Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

(bimatoprost + brimonidine tartarate + timolol maleate) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(bimatoprost + timolol maleate) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(carteolol hydrochloride + latanoprost) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(latanoprost + netarsudil mesylate) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(latanoprost + timolol maleate) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(latanoprost + trabodenoson) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AMA-0076 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Antisense Oligonucleotides to Inhibit P16INK4a for Primary Open-Angle Glaucoma (POAG) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

bamosiran - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

bimatoprost - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

bimatoprost SR - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DE-117 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

decorin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Glaucoma-GT - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ISTH-0036 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

latanoprost - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

latanoprost - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

latanoprost SR - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

latanoprost SR - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

latanoprostene bunod - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

levobetaxolol hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LX-7101 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MAN-01 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MGV-354 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

netarsudil mesylate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

OPA-6566 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PRO-067 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

R-801 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RG-4929 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ripasudil - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RO-5093151 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SAR-366234 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Sepetaprost - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SNJ-1656 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

trabodenoson - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

travoprost - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

travoprost SR - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

travoprost XR - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Open-Angle Glaucoma - Dormant Projects

Open-Angle Glaucoma - Discontinued Products

Open-Angle Glaucoma - Product Development Milestones

Featured News & Press Releases

Apr 26, 2016: Inotek Pharmaceuticals Announces Poster Presentations on Trabodenoson at the ARVO 2016 Annual Meeting

Apr 11, 2016: Inotek Pharmaceuticals Announces the Journal of Ocular Pharmacology and Therapeutics has Published its Phase 2 Data for Trabodenoson in Patients with Glaucoma and Ocular Hypertension

Mar 03, 2016: Aerie Pharmaceuticals Announces Availability on Its Website of Abstracts to be Presented at the American Glaucoma Society 26th Annual Meeting

Feb 22, 2016: Aerie Pharmaceuticals Announces Four New Abstracts to be Presented at the American Glaucoma Society 26th Annual Meeting Next Week

Mar 10, 2010: Qlt Announces Phase II Clinical Trial Results And Development Plans For The Punctal Plug Delivery System

Jul 28, 2009: Qlt Announces Interim Data From A Phase II Clinical Trial And A Device Study For A Punctal Plug Drug Delivery System

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Number of Products under Development for Open-Angle Glaucoma, H2 2016

Number of Products under Development for Open-Angle Glaucoma - Comparative Analysis, H2 2016

Number of Products under Development by Companies, H2 2016

Number of Products under Development by Companies, H2 2016 (Contd..1)

Number of Products under Investigation by Universities/Institutes, H2 2016

Comparative Analysis by Late Stage Development, H2 2016

Comparative Analysis by Clinical Stage Development, H2 2016

Comparative Analysis by Early Stage Development, H2 2016

Products under Development by Companies, H2 2016

Products under Development by Companies, H2 2016 (Contd..1)

Products under Investigation by Universities/Institutes, H2 2016

Open-Angle Glaucoma - Pipeline by Aerie Pharmaceuticals, Inc., H2 2016

Open-Angle Glaucoma - Pipeline by Allergan Plc, H2 2016

Open-Angle Glaucoma - Pipeline by Amakem NV, H2 2016

Open-Angle Glaucoma - Pipeline by Bausch & Lomb Incorporated, H2 2016

Open-Angle Glaucoma - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016

Open-Angle Glaucoma - Pipeline by Glaukos Corporation, H2 2016

Open-Angle Glaucoma - Pipeline by Inotek Pharmaceuticals Corporation, H2 2016

Open-Angle Glaucoma - Pipeline by Isarna Therapeutics GmbH, H2 2016

Open-Angle Glaucoma - Pipeline by Kowa Company, Ltd., H2 2016

Open-Angle Glaucoma - Pipeline by Laboratoires Thea S.A., H2 2016

Open-Angle Glaucoma - Pipeline by Laboratorios Sophia S.A. de C.V., H2 2016

Open-Angle Glaucoma - Pipeline by Lee's Pharmaceutical Holdings Limited, H2 2016

Open-Angle Glaucoma - Pipeline by Lexicon Pharmaceuticals, Inc., H2 2016

Open-Angle Glaucoma - Pipeline by Ocular Therapeutix, Inc., H2 2016

Open-Angle Glaucoma - Pipeline by Otsuka Holdings Co., Ltd., H2 2016

Open-Angle Glaucoma - Pipeline by Oxford BioMedica Plc, H2 2016

Open-Angle Glaucoma - Pipeline by Sanofi, H2 2016

Open-Angle Glaucoma - Pipeline by Santen Pharmaceutical Co., Ltd., H2 2016

Open-Angle Glaucoma - Pipeline by Senju Pharmaceutical Co., Ltd., H2 2016

Open-Angle Glaucoma - Pipeline by Sun Pharma Advanced Research Company Ltd., H2 2016

Open-Angle Glaucoma - Pipeline by Sylentis S.A.U., H2 2016

Open-Angle Glaucoma - Pipeline by ViSci Ltd., H2 2016

Assessment by Monotherapy Products, H2 2016

Assessment by Combination Products, H2 2016

Number of Products by Stage and Target, H2 2016

Number of Products by Stage and Mechanism of Action, H2 2016

Number of Products by Stage and Route of Administration, H2 2016

Number of Products by Stage and Molecule Type, H2 2016

Open-Angle Glaucoma - Dormant Projects, H2 2016

Open-Angle Glaucoma - Dormant Projects (Contd..1), H2 2016

Open-Angle Glaucoma - Discontinued Products, H2 2016 117List of Figures

Number of Products under Development for Open-Angle Glaucoma, H2 2016

Number of Products under Development for Open-Angle Glaucoma - Comparative Analysis, H2 2016

Number of Products under Development by Companies, H2 2016

Number of Products under Investigation by Universities/Institutes, H2 2016

Comparative Analysis by Late Stage Development, H2 2016

Comparative Analysis by Clinical Stage Development, H2 2016

Comparative Analysis by Early Stage Products, H2 2016

Assessment by Monotherapy Products, H2 2016

Assessment by Combination Products, H2 2016

Number of Products by Top 10 Targets, H2 2016

Number of Products by Stage and Top 10 Targets, H2 2016

Number of Products by Top 10 Mechanism of Actions, H2 2016

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016

Number of Products by Routes of Administration, H2 2016

Number of Products by Stage and Routes of Administration, H2 2016

Number of Products by Molecule Types, H2 2016

Number of Products by Stage and Molecule Types, H2 2016
Note: Product cover images may vary from those shown
3 of 6

Loading
LOADING...

4 of 6

FEATURED COMPANIES

  • Allergan Plc
  • F. Hoffmann-La Roche Ltd.
  • Isarna Therapeutics GmbH
  • Laboratoires Thea S.A.
  • Otsuka Holdings Co., Ltd.
  • Sanofi
  • MORE
Open-Angle Glaucoma pipeline therapeutics constitutes close to 38 molecules. Out of which approximately 36 molecules are developed by Companies and remaining by the Universities/Institutes. Our latest report Open-Angle Glaucoma – Pipeline Review, H2 2016, outlays comprehensive information on the therapeutics under development for Open-Angle Glaucoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.

Open-Angle Glaucoma Open-angle glaucoma also called wide-angle glaucoma, this is the most common type of glaucoma. The structures of the eye appear normal, but fluid in the eye does not flow properly through the drain of the eye, called the trabecular meshwork. Signs and symptoms include gradual loss of peripheral vision, usually in both eyes and tunnel vision in the advanced stages. Risk factors include age, family history of glaucoma, long-term corticosteroid use and elevated internal eye pressure (intraocular pressure). The molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I and Preclinical stages are 2, 1, 9, 17, 4 and 3 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively.

Furthermore, this report also reviews of key players involved in therapeutic development for Open-Angle Glaucoma and features dormant and discontinued projects. Driven by data built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Product cover images may vary from those shown
5 of 6
Aerie Pharmaceuticals, Inc.
Allergan Plc
Amakem NV
Bausch & Lomb Incorporated
F. Hoffmann-La Roche Ltd.
Glaukos Corporation
Inotek Pharmaceuticals Corporation
Isarna Therapeutics GmbH
Kowa Company, Ltd.
Laboratoires Thea S.A.
Laboratorios Sophia S.A. de C.V.
Lee's Pharmaceutical Holdings Limited
Lexicon Pharmaceuticals, Inc.
Ocular Therapeutix, Inc.
Otsuka Holdings Co., Ltd.
Oxford BioMedica Plc
Sanofi
Santen Pharmaceutical Co., Ltd.
Senju Pharmaceutical Co., Ltd.
Sun Pharma Advanced Research Company Ltd.
Sylentis S.A.U.
ViSci Ltd.
Note: Product cover images may vary from those shown
6 of 6
Note: Product cover images may vary from those shown
Adroll
adroll